Acetylation News and Research

RSS

Acetylation (or in IUPAC nomenclature ethanoylation) describes a reaction that introduces an acetyl functional group into an organic compound. Deacetylation is the removal of the acetyl group.

Accelerator announces Series A Preferred Stock financing of Acylin

Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.

1 Dec 2010

Researchers identify molecular signals that impact male fertility: Research

Male infertility is a common medical problem, affecting millions of men in the United States annually. Its causes include an inability to make productive sperm. Now, using yeast as a model organism, researchers at the University of Pennsylvania School of Medicine are beginning to identify the molecular signals that could in part underlie that problem.

25 Aug 2010

Research on fruit fly provides inroads into understanding cancer development

Changes to proteins in a cell underlay many cancers. Rui Martinho at the Instituto Gulbenkian de Ci-ncia (IGC), in Portugal, in collaboration with researchers in Ghent (Belgium) and Bergen (Norway) will use the fruit fly to understand exactly how changes to proteins, identified in the test-tube, impact on the way cells divide in a living organism

24 Aug 2010

Protein acetylation not rare in bacteria

Lowly bacteria are turning out to be much more complex than previously thought.

13 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

Researchers identify major indicator of heart failure and aortic aneurysms

Case Western Reserve University School of Medicine researchers have identified a major indicator of two deadly diseases of the heart and blood vessels: heart failure and aortic aneurysm. The absence of the Kruppel-like Factor 15, when combined with stress, leads to both heart failure and aortic aneurysms.

8 Apr 2010

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Scientists at the University of Delaware have developed a new method for producing proteins critical to research on cancer, Alzheimer's, and other diseases.

3 Apr 2010

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

A paper published online today in Molecular Cell proposes that Methyl CpG binding protein 2 (MeCP2) impacts the entire genome in neurons, rather than acting as a regulator of specific genes. Mutations in MeCP2 cause the autism spectrum disorder Rett Syndrome as well as some cases of neuropsychiatric problems including autism, schizophrenia and learning disabilities.

26 Feb 2010

Cellular metabolism plays a key role in cancer development

It is not unusual to hear people blame their metabolism after gaining a few pounds. But changes in metabolism - the process that shapes how our bodies turn food into energy -- can have much more sinister effects than making it hard to fit into your favorite jeans.

19 Feb 2010

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.

11 Feb 2010

IKK phosphorylate: A double-edged sword in Huntington's disease

The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).

22 Dec 2009

Oncologists optimistic about the potential of clinical trials for personalized medicine

According to a national poll of oncologists and clinical research professionals, there is a high level of optimism about the potential of clinical trials for personalized medicine. While oncologists view cost as a barrier to treatment and research, they think policy initiatives are opportunities to effectively promote personalized medicine.

4 Dec 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

HDAC inhibitors: New therapy for treating breast cancer

A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself, researchers say.

17 Nov 2009

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with “Epigenetics & Chromatin Modification” at the Society for Neuroscience’s, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.

15 Oct 2009

Rush University receives grants to study how epigenomic changes define cognitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

1 Oct 2009

Study on how epigenetic changes contribute to congnitive decline

28 Sep 2009

Researchers discover benefits of treating Alzheimer's disease with cancer drug

A drug now used to treat cancer may also be able to restore memory deficits in patients with Alzheimer's disease, according to a new study conducted by scientists at Columbia University Medical Center, which appeared in the September issue of the Journal of Alzheimer's Disease: Volume 18:1.

8 Sep 2009